SCHEMBL1697200

SCHEMBL1697200

Cc1c(Cl)cc(-c2ccccc2)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.50
AKR1C2 P52895 3/20 0.47
AKR1C1 Q04828 3/20 0.47
CYP1A2 P05177 1/20 0.46
ALDH1A1 P00352 4/20 0.45
CYP2A6 P11509 1/20 0.42
AHR P35869 1/20 0.41
KDM4E B2RXH2 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
FTO Q9C0B1 2/20 0.41
RHEB Q15382 1/20 0.41
MEN1 O00255 2/20 0.39
HPGD P15428 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12925902 0.82 ESR2 (0.44) ESR2AKR1C2AKR1C1CYP1A2CYP2A6
SCHEMBL27832590 0.80 ALDH1A1 (0.51) ESR2CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4458296 0.79 AHR (0.64) ESR2AKR1C2AKR1C1CYP1A2ALDH1A1
SCHEMBL16939188 0.77 ESR2 (0.52) ESR2AKR1C2AKR1C1CYP1A2ALDH1A1
SCHEMBL16934967 0.77 ESR2 (0.52) ESR2AKR1C2AKR1C1CYP1A2ALDH1A1
SCHEMBL2205354 0.76 AHR (0.43) AKR1C2AKR1C1ALDH1A1AHRKDM4E
SCHEMBL31614097 0.76 ESR2 (0.57) ESR2AKR1C2AKR1C1CYP1A2ALDH1A1
SCHEMBL21872091 0.76 ESR2 (0.47) ESR2AKR1C2AKR1C1CYP1A2ALDH1A1
SCHEMBL1755256 0.76 ESR2 (0.57) ESR2AKR1C2AKR1C1CYP1A2ALDH1A1
SCHEMBL10492510 0.75 MAPT (0.50) ALDH1A1KDM4ESMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9671693-B2 Resist composition and method for producing resist pattern SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-06-06 US disclosed
US-8951709-B2 Resist composition and method for producing resist pattern SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-02-10 US disclosed
US-8530138-B2 Salt and photoresist composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-09-10 US disclosed
US-8431326-B2 Salt and photoresist composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-04-30 US disclosed
US-8426106-B2 Photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-04-23 US disclosed
US-8426106-B2 Photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-04-23 US disclosed
US-20120156620-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-20120100482-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-04-26 US disclosed
US-20120088190-A1 SALT AND PHOTORESIST COMPOSITION COMPRISING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-04-12 US disclosed
US-20120052440-A1 SALT AND PHOTORESIST COMPOSITION COMPRISING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-03-01 US disclosed
US-20110091807-A1 PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-21 US disclosed
US-20110091807-A1 PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052440-A1 SALT AND PHOTORESIST COMPOSITION COMPRISING THE SAME C1S, C1R, CLIC1 ESR2 2342/4885AKR1C2 932/4885AKR1C1 799/4885
US-20110091807-A1 PHOTORESIST COMPOSITION H1-0, H1-2, H1-3 ESR2 2199/4885AKR1C2 1697/4885AKR1C1 1118/4885
US-20120088190-A1 SALT AND PHOTORESIST COMPOSITION COMPRISING THE SAME AFF1, FGFR1, FRG1 ESR2 1980/4885AKR1C2 767/4885AKR1C1 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.